Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABO 2203

Drug Profile

ABO 2203

Alternative Names: ABO-2203; mRNA encoding CD19/CD3 T cell engager - Suzhou Guangxin Biosciences

Latest Information Update: 24 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Guangxin Biosciences
  • Class Antineoplastics; Immunotherapies; Recombinant fusion proteins; RNA
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma
  • Preclinical Autoimmune disorders

Most Recent Events

  • 26 May 2025 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (IV) (NCT07072169)
  • 26 May 2025 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (SC) (NCT07072169)
  • 31 Dec 2024 Suzhou Guangxin Biosciences plans phase-0 trial for Autoimmune disorders (Treatment-resistant) in China (Parenteral, Injection) in December 2024 (NCT06747156)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top